Alliance Pharma Eyes OTC Acquisitions Following Strong 2021
UK-based Alliance Pharma saw sales rise double-digits in 2021, with acquisitions bolstering the performance of its established brands. Going into 2022, the company says it is in a strong position to pursue M&A in the consumer health space.
You may also be interested in...
Alliance Pharma Enhances US Offering With Perrigo's Scar Treatments
Alliance Pharma has delivered on its commitment to expand its US operations with a deal for Perrigo's ScarAway and Kelo-cote brands. For Perrigo, the divestment brings its acquisition of HRA Pharma a step closer by satisfying competition concerns.
Alliance Pharma Weighing US Acquisition Opportunity
UK-based Alliance Pharma is in talks to expand its burgeoning US consumer health offering with a bolt on acquisition.
Alliance Pharma Grows In US With Amberen Menopause Supplement
UK-based Alliance Pharma has strengthened its US offering by acquiring Biogix and its Amberen menopause supplement.